Videos

Key Data and Outcomes from the GRIFFIN Trial

Subject-matter experts share their perspectives on treatment selection for patients with NDMM.

Luciano Costa, MD, PhD;Timothy Schmidt, MD

Relapsed/Refractory MM: Safety and Efficacy Data From RedirecTT-1

A summary of updates from the GRIFFIN trial evaluating D-RVd in clinically relevant NDMM patient subgroups.

Ajai Chari, MD;Carolina D. Schinke, MD

Relapsed/Refractory Multiple Myeloma: Sequencing BCMA-Targeting Therapies

Centering discussion on RedirecTT-1, expert hematologist-oncologists consider safety and efficacy data with the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Ajai Chari, MD;Carolina D. Schinke, MD

The Potential Role of Menin Inhibitors in the Front-Line Treatment of AML

Shared perspective on available novel therapies in relapsed/refractory multiple myeloma and how best to sequence these agents.

Naval Daver, MD;Harry P. Erba, MD, PhD;Dan Pollyea, MD, MS;Eunice S. Wang, MD

First-Line Treatment Options for AML With KMT2a Rearrangements

The expert panel review recently reported data from clinical trials evaluating menin inhibitors, including ziftomenib and revumenib, in the treatment of relapsed AML and how these treatments may fit into first-line settings.

Naval Daver, MD;Harry P. Erba, MD, PhD;Dan Pollyea, MD, MS;Eunice S. Wang, MD

Addressing Unmet Needs and Disparities Across Patient Populations in Multiple Myeloma

Daniel Pollyea, MD, MS, discusses first-line treatment options for patients with AML with KMT2a rearrangements.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD

Optimizing Treatment Duration and Adverse Effect Management in Patients with NDMM

Closing thoughts on unmet needs in the multiple myeloma space, particularly disparities in the care of patients with MM of racial and ethnic minorities.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD

Selecting an Appropriate Frontline Treatment Regimen for Patients With Advanced RCC

Dr. Cook and Dr. Pianko share their perspectives on optimizing treatment strategies for individual patients in order to maximize response and mitigate adverse events.

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

Comparing IO/TKI and IO/IO First-Line Treatment Regimens in Advanced RCC

Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.

Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD

Non-Immunotherapy Interventions May Successfully Target Renal Cell Carcinoma

Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.

A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Rana R. McKay, MD

Expert Describes Direct Tumor Killing Strategies in Renal Cell Carcinoma

A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Rana R. McKay, MD

NDMM Risk-Stratification and Other Factors Informing Treatment Selection

Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Sagar Lonial, MD, FACP;Nisha Joseph, MD;Jonathan Kaufman, MD;Ajay K. Nooka, MD

Key Trial Data Guiding Treatment Decisions for Patients with NDMM

Defining transplant eligibility, explaining the role of transplant in NDMM, and differentiating between high- and low-risk MM.

Sagar Lonial, MD, FACP;Nisha Joseph, MD;Jonathan Kaufman, MD;Ajay K. Nooka, MD

Emerging BCMA Targeting Bispecifics in Multiple Myeloma

Thoughtful discussion centered around recently presented updates to the GRIFFIN, MASTER, and GMMG-CONCEPT studies in NDMM patients.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Factors in Selecting Frontline Therapy for Advanced Bladder Cancer

Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.

Petros Grivas, MD, PhD;Emily S. Weg, MD;Lisa Adams, PA-C;Nerina T. McDonald, PA-C

Best Supportive Care for Patients With Bladder Cancer

Centering focus on the first-line treatment armamentarium, key opinion leaders consider factors that aid in the selection of best therapy for patients with advanced bladder cancer.

Petros Grivas, MD, PhD;Emily S. Weg, MD;Lisa Adams, PA-C;Nerina T. McDonald, PA-C

Supportive Care Strategies for Patients with MM on Bispecifics Treatment

A brief discussion on supportive care available to patients with bladder cancer and the role it plays within the treatment pathway.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Belzutifan Generates ‘Excitement’ in Renal Cell Carcinoma, Expert Says

Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.

Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.

Rana R. McKay, MD

Unmet Needs in the Treatment of Multiple Myeloma

Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM

The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

Trial Data and Experience With Amivantamab in EGFR Exon20+ NSCLC

Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.

Joshua K. Sabari, MD;Misako Nagasaka, MD

First- and Second-Line Treatment Options for EGFR Exon20+ NSCLC

Expert perspectives on clinical trial data and personal experience with amivantamab in the setting of EGFR Exon20+ non–small cell lung cancer.

Joshua K. Sabari, MD;Misako Nagasaka, MD

Relapsed/Refractory CLL: Overview of the Treatment Landscape

Key opinion leaders in non–small cell lung cancer management reflect on the current first- and second-line treatment options available to patients with EGFR Exon20+ disease.

Alan P. Skarbnik, MD, Novant Health Cancer Institute;Ryan W. Jacobs, MD, Atrium Health Levine Cancer Institute

Patient Monitoring after Adjuvant Chemotherapy in Colorectal Cancer

A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Joleen M. Hubbard, MD;Aparna Raj Parikh, MD, MS

CAR T-Cell Therapy in Transplant-Ineligible Patients with MM

Medical oncologists who specialize in gastrointestinal cancers offer clinical insights on monitoring patients following treatment with adjuvant chemotherapy.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Treatment Considerations for Transplant-Ineligible Patients with MM

Nausheen Ahmed, MD, and Al-Ola Abdallah, MD, discuss the use of CAR T-cell therapy in patients with transplant-ineligible multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Relapsed/Refractory Multiple Myeloma: Incidence of CRS in MajesTEC-1

The expert panel gives an overview of factors that influence treatment decisions in patients with transplant-ineligible multiple myeloma.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

Unmet Needs and Future Directions in the Management of Multiple Myeloma

Focused discussion on the advent of cytokine release syndrome in MajesTEC-1 and how it compared to the benefits derived from teclistamab therapy.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Colorectal Cancer Treatment Considerations Following IDEA Collaboration Analysis

Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Joleen M. Hubbard, MD;Aparna Raj Parikh, MD, MS